MX2022011826A - Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo. - Google Patents

Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo.

Info

Publication number
MX2022011826A
MX2022011826A MX2022011826A MX2022011826A MX2022011826A MX 2022011826 A MX2022011826 A MX 2022011826A MX 2022011826 A MX2022011826 A MX 2022011826A MX 2022011826 A MX2022011826 A MX 2022011826A MX 2022011826 A MX2022011826 A MX 2022011826A
Authority
MX
Mexico
Prior art keywords
ahr
aryl hydrocarbon
hydrocarbon receptor
receptor modulators
disease
Prior art date
Application number
MX2022011826A
Other languages
English (en)
Inventor
Hyounmie Doh
Seunghyun Song
Jung-Sang Park
Daewon Cha
Wonhyung Lee
Min Sung Joo
Taeyoung Yoon
Hyun Jung Sung
Bo Ryeong Lee
Yoonjung Kim
Ji Hoon Choi
Hyeon Seok Jung
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of MX2022011826A publication Critical patent/MX2022011826A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con compuestos novedosos efectivos como moduladores del receptor de hidrocarburos de arilo (AhR), composición farmacéutica que comprende los compuestos para la modulación de AhR, o la prevención o tratamiento de una enfermedad, trastorno o afección asociada con la actividad de AhR, como ingrediente activo, y por lo tanto, puede ser útil como medicamento para la prevención o el tratamiento de una enfermedad, trastorno o afección asociada con la actividad de AhR, en particular, cáncer, afección cancerosa, tumor, enfermedad fibrótica, afección con respuestas inmunitarias desreguladas, etc.
MX2022011826A 2020-03-27 2021-03-29 Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo. MX2022011826A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000584P 2020-03-27 2020-03-27
PCT/KR2021/003883 WO2021194326A1 (en) 2020-03-27 2021-03-29 Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators

Publications (1)

Publication Number Publication Date
MX2022011826A true MX2022011826A (es) 2022-10-18

Family

ID=77892076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011826A MX2022011826A (es) 2020-03-27 2021-03-29 Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo.

Country Status (10)

Country Link
US (1) US20230150970A1 (es)
EP (1) EP4126839A4 (es)
JP (1) JP2023520988A (es)
KR (1) KR20230005844A (es)
CN (1) CN115397818A (es)
AU (1) AU2021242143A1 (es)
BR (1) BR112022019387A2 (es)
CA (1) CA3176957A1 (es)
MX (1) MX2022011826A (es)
WO (1) WO2021194326A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
AU2002318041B2 (en) * 2001-07-13 2008-01-03 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
KR101328978B1 (ko) * 2010-10-26 2013-11-13 삼성디스플레이 주식회사 유기 발광 소자
AU2015250994B2 (en) * 2014-04-22 2018-12-20 Torqur Ag Novel manufacturing process for triazine, pyrimidine and pyridine derivatives
US11008280B2 (en) * 2016-04-26 2021-05-18 Duk San Neolux Co., Ltd. Compound for organic electric element, organic electric element using same, and electronic device comprising same organic electronic element
CN109863140B (zh) * 2016-05-25 2023-02-21 拜耳医药股份有限公司 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺
PL3570844T3 (pl) * 2017-01-20 2024-02-26 Arcus Biosciences, Inc. Azolopirymidyna do leczenia zaburzeń związanych z nowotworami
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
TWI778050B (zh) * 2017-04-21 2022-09-21 美商醫肯納腫瘤學公司 吲哚ahr抑制劑及其用途
CN110343095A (zh) * 2018-04-08 2019-10-18 中国科学院上海药物研究所 一类精氨酸甲基转移酶抑制剂及其药物组合物和用途

Also Published As

Publication number Publication date
BR112022019387A2 (pt) 2022-11-16
EP4126839A1 (en) 2023-02-08
KR20230005844A (ko) 2023-01-10
EP4126839A4 (en) 2024-04-17
CN115397818A (zh) 2022-11-25
WO2021194326A1 (en) 2021-09-30
JP2023520988A (ja) 2023-05-23
AU2021242143A1 (en) 2022-10-20
US20230150970A1 (en) 2023-05-18
CA3176957A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2022012739A (es) Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
Good et al. Intralesional agents in the management of cutaneous malignancy: a review
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
WO2019099977A3 (en) Indole compounds as aryl hydrocarbon receptor (ahr) modulators
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
Vadhan‐Raj et al. Clinical applications of palifermin: amelioration of oral mucositis and other potential indications
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
EP4324460A3 (en) Sodium bicarbonate for use in the treatment of gout and related disorders
MY171356A (en) Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
Greb et al. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum.
WO2017062619A3 (en) Combination therapy for the treatment of cancer
CR20230057A (es) Compuestos tríciclicos de urea como inhibidores de jak2 v617f
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
CR20230404A (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2022014925A (es) Moduladores de il-17a.
MX2022014924A (es) Moduladores de il-17a.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
PH12021551446A1 (en) Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
BR112013024909A2 (pt) composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
MX367469B (es) Compuestos furanilo y su uso.
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.